Joint Statement on Prioritization of Canadians with Lung Disease in COVID-19 Rollout
As part of the Canadian Thoracic Society’s COVID-19 Respiratory Roundtable panel representing Canadians living with lung disease, Asthma Canada signed a joint statement titled Prioritization of Canadians with Lung Disease in COVID-19 Vaccination Rollout. Alongside other lung health organizations, Asthma Canada is urging federal, provincial and territorial governments to prioritize people living with lung disease who are at higher risk for more serious COVID-19 complications in the vaccination rollout. From Canadians living with a lung disease such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, lung cancer, pulmonary fibrosis, pulmonary hypertension, and pre- and post-lung transplant, there is widespread concern regarding when in the vaccine rollout in the provinces and territories they will have the opportunity to receive the vaccine.
We will continue to advocate for our community on this subject and will share more information as it becomes available.
Canadians living with pre-existing conditions such as a lung disease and their caregivers have faced heavy burdens throughout the pandemic.
This is why alongside a roundtable of organizations who represent and work closely with Canadians living with these diseases, we’re urging governments across Canada to prioritize these individuals in COVID-19 vaccination programs.
Read our joint statement below.